In the present study, we establish that the AAV vector mediated delivery and expression of cetuximab prolongs survival in human GBM mouse models with U87MG cell line modified to express the EGFR when vector and cells are administered concurrently or when vector is administered after the tumor cells are administered, modelling a therapeutic intervention. The gene discussed is EGFR; the disease is glioblastoma.